scholarly journals The Treatment of Macrolide-Resistant Mycoplasma Pneumoniae Pneumonia in Children

2020 ◽  
Author(s):  
Fang-fang DAI ◽  
Feng-qin LIU ◽  
Xing CHEN ◽  
Juan YANG ◽  
Ke WANG ◽  
...  
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Adverse Reactions ◽  
Clinical Symptoms ◽  
Gastrointestinal Symptoms ◽  
Blood Parameters ◽  
Oral Route ◽  
Mycoplasma Pneumonia ◽  
Liver And Kidney ◽  
Medical University

Abstract Objective: To evaluate the efficacy and safety of levofloxacin in children with macrolide-resistant Mycoplasma pneumoniae pneumonia. Methods: We retrospectively enrolled six confirmed cases of refractory Mycoplasma pneumoniae pneumonia (n=6) who were admitted in the pediatric respiratory ward of Shandong provincial hospital Affiliated to Shandong first Medical University between January 1st, 2020and February 29th, 2020. Levofloxacin was given to the patients through the intravenous or oral route as per the following dosages :< 5 years, 8-10 mg/kg q12hours; > 5 years, 8-10 mg/kg, qd for ten days. The clinical data were collected and analyzed. Results: The average age of the enrolled cases was six years and nine months (range, four years, and seven months to eleven years and seven months). All cases were found to be drug-resistant and were treated with azithromycin combined with antibacterial drugs. Levofloxacin was used in the patient’s refractory to macrolide antibiotics. The temperature of five cases returned to normal 1 to 2 days after treatment with levofloxacin, and the imaging of the four cases showed expected improvements. The gastrointestinal symptoms, neurological manifestations, joint symptoms, blood parameters, liver and kidney functions, and exercise conditions of the children were closely monitored. The follow-up time of the patients ranged from one week to five months. No drug-related adverse reactions were observed in patients during treatment or during follow up.Conclusions: The clinical symptoms and imaging significantly improved after treatment with levofloxacin, and no drug-related adverse reactions were observed. Levofloxacin proved to be an effective and safe drug in the treatment of children with macrolide-resistant mycoplasma pneumonia.

IDIOPATHIC CELIAC DISEASE

PEDIATRICS ◽  
1953 ◽  
Vol 11 (3) ◽  
pp. 224-237
Author(s):  
PAUL A. DI SANT'AGNESE
Keyword(s):  
Celiac Disease ◽  
Clinical Symptoms ◽  
Respiratory Infections ◽  
Gastrointestinal Symptoms ◽  
Adult Life ◽  
Early Years ◽  
Clinical Recovery ◽  
Upper Respiratory ◽  
Latent Phase

The mortality and course of the illness of 58 patients with celiac disease, previously reported, are described. Three patients died; the remaining 55 went on to clinical recovery. The greatest clinical gains were made by these cases in the 6 to 24 months following initiation of treatment, but the abnormal character of the stools persisted for months or years. Relapses were not uncommon during the early years of improvement following upper respiratory infections or dietary indiscretions. The results of the follow-up study of 23 patients, 3 to 11 years after the original admission to Babies Hospital, are reported. It was found that despite remission of clinical symptoms, many abnormal laboratory and roentgenographic findings persisted (termed "latent phase of celiac disease"). It is reasonable to expect that some patients who have had severe celiac disease during infancy or early childhood may experience a recurrence of gastrointestinal symptoms in adult life.

scholarly journals Brucellar reproductive system injury: A retrospective study of 22 cases and review of the literature

2020 ◽  
Vol 48 (6) ◽  
pp. 030006052092454
Author(s):  
Yan Zhou ◽  
Songsong Xie ◽  
Rongjiong Zheng ◽  
Qinqi Dai ◽  
Zheng Xu ◽  
...  
Keyword(s):  
Reproductive System ◽  
Chronic Prostatitis ◽  
Clinical Symptoms ◽  
Drug Regimen ◽  
Review Of The Literature ◽  
Male Patients ◽  
Patient Prognosis ◽  
Medical University ◽  
Lost To Follow Up

Objective We aimed to describe the clinical characteristics and prognosis of 22 patients with Brucella-induced reproductive system injury. Methods We assessed 22 patients with reproductive system injury between 2010 and 2018 at The First Affiliated Hospital of Xinjiang Medical University. Results The disease is predominant in men. Male patients had orchitis, erectile dysfunction, prostatitis, and urethral stricture, while female patients had vaginitis and cervicitis. Some patients had laboratory abnormalities and liver injury. Patients received combination therapy of rifampicin and doxycycline. Doxycycline combined with levofloxacin or moxifloxacin was administered to patients with rifampicin intolerance. All patients had received antibiotic therapy for at least 6 weeks. One patient was lost to follow-up, one patient relapsed because of osteoarthropathy, and one patient had dysuria resulting from chronic prostatitis. The clinical symptoms resolved in the other patients, and the overall patient prognosis was good. Conclusion Clinicians should pay attention to brucellosis-induced reproductive system damage. The two-drug regimen of rifampicin+doxycycline is recommended for these patients. Doxycycline combined with levofloxacin or moxifloxacin should be used in patients with brucellosis-induced reproductive system damage who have rifampicin intolerance. The treatment course should be at least 6 weeks.

scholarly journals Tolerance and safety of the potentially probiotic strainLactobacillus rhamnosusPRSF-L477: a randomised, double-blind placebo-controlled trial in healthy volunteers

2010 ◽  
Vol 104 (12) ◽  
pp. 1806-1816 ◽  
Author(s):  
Richèle D. Wind ◽  
Hermien Tolboom ◽  
Ingo Klare ◽  
Geert Huys ◽  
Jan Knol
Keyword(s):  
Controlled Trial ◽  
Gastrointestinal Symptoms ◽  
Lactobacillus Rhamnosus ◽  
Probiotic Strain ◽  
Blood Parameters ◽  
Serious Adverse Events ◽  
Double Blind ◽  
Liver And Kidney ◽  
Haematological Analysis ◽  
Susceptibility Profiles

In Europe, the speciesLactobacillus rhamnosusis currently on the Qualified Presumption of Safety list used by the European Food Safety Authority (EFSA) for internal safety assessment, but according to the EFSA the species should remain a topic of surveillance. In the present study, the safety and tolerance of the potentially probiotic strainL. rhamnosusPRSF-L477 was investigated in a placebo-controlled double-blind volunteer trial following FAO/WHO guidelines. A total of thirty-four subjects received daily doses of 1 × 1011colony-forming units (cfu) ofL. rhamnosusPRSF-L477 (n17) or placebo (n17) for a period of 3 weeks, followed by a wash-out period of another 3 weeks. A questionnaire on gastrointestinal tolerance and a diary was kept daily to record compliance throughout these 6 weeks. Faecal and blood samples were collected for microbiological and haematological analysis. The recorded gastrointestinal symptoms, defecation frequency and stool consistency were not influenced indicating thatL. rhamnosusPRSF-L477 was well tolerated. The speciesL. rhamnosuswas detected in the faeces of sixteen out of seventeen subjects of the probiotic group during the intervention period. Using pulsed-field gel electrophoresis, re-isolates ofL. rhamnosusPRSF-L477 were confirmed in nine of these subjects. Antibiotic susceptibility profiles of these re-isolates were unchanged compared with PRSF-L477. No clinically relevant changes in blood parameters such as liver and kidney function and no serious adverse events appeared during and after administration. Therefore, we conclude thatL. rhamnosusPRSF-L477 can safely be administrated to healthy subjects at a daily dose of 1 × 1011 cfu.

scholarly journals Children and pregnant women are more likely to develop severe Mycoplasma pneumoniae Pneumonia：Mycoplasma pneumoniae infection in Suzhou: 2014 to 2018

2021 ◽  
Author(s):  
yantian Lv ◽  
Xiaojing Sun ◽  
Ying Chen ◽  
Ting Ruan ◽  
Guopeng Xu ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Mycoplasma Pneumoniae ◽  
Respiratory Tract Infections ◽  
Age Distribution ◽  
Gender And Age ◽  
Mycoplasma Pneumonia ◽  
Tract Infections ◽  
Medical University ◽  
Annual Proportion ◽  
Mycoplasma Pneumoniae Pneumonia

Abstract Purpose To study the epidemic characteristics of Mycoplasma pneumonia(MP) in the whole population and the clinical characteristics of severe Mycoplasma pneumoniae pneumonia(SMMP). Methods We retrospectively analyzed 56474 patients with respiratory tract infections (RTIS) of the affiliated hospital of Nanjing medical university from 2014 to 2018. Serum particle agglutination (PA) was used to detect MP specific IgM antibody to confirm MP infection. Results A total of 56474 patients with RTIs were enrolled, and 15857 (28.13%) of patients with MP-IgM positive were detected. From 2014 to 2018, the annual proportion of MP RITs was 23.60%, 28.18%, 38.08%, 27.05% and 23.44%. In terms of seasonal distribution, April-June and September-November were the peak seasons each year. The proportion of MP RITs of children was significantly higher than that of adults in almost every year. The proportion of MP RITs of female was significantly higher in children and adults. The peak age of MP infection was between the age of 4 and 14 years old. There were 216 cases of SMPP patients, including 198 children and 18 adults (8 cases of pregnant women). Children and pregnant women were more likely to develop severe Mycoplasma pneumonia. SMMP patients had more extrapulmonary symptoms, multilobar infiltrates and pleural effusion, and increased CRP, LDH and WBC(p < 0.05). Conclusions This study shows that MP infection has a seasonal, gender, and age distribution trend, and SMMP is more likely to occur in children and pregnant women. Understanding these characteristics will contribute to timely diagnose and treat MP infection.

scholarly journals Clinical features and outcome of fecal retention in infancy

2020 ◽  
Author(s):  
Lu Ren ◽  
Lan-Lan Geng ◽  
hong-li Wang ◽  
si-tang Gong ◽  
Jing Xie ◽  
...  
Keyword(s):  
Medical Record ◽  
Electronic Medical Record ◽  
Clinical Features ◽  
Clinical Symptoms ◽  
Gastrointestinal Symptoms ◽  
Treatment Rate ◽  
Record System ◽  
Significant Difference ◽  
Normal Defecation

Abstract 1) Background: To understand the clinical features and outcome of fecal retention in infancy(FRI), so as to guide the focus and intervention methods of such infants.2) Methods: The electronic medical record system(EMRS)was used to collect and screen out cases diagnosed as fecal retention from June 2018 to June 2019 in outpatient clinic of our hospital. The age, feeding method, frequency and traits of stool, and accompanying symptoms were recorded. The changes of clinical symptoms, medical examinations and drug treatment by the age of 1 year were investigated by means of electronic medical record review and telephone follow-up.3) Results: A total of 286 infants were enrolled, 7 were lost to follow-up, and 279 were effectively followed up. There were 157 males and 129 females, with an age of 3.6 ± 1.5 months. The average stool frequency was 5.9 ± 1.8 days. 63.3% of the infants were breast-fed, 16.8% were formula-fed, and the rest were mixed-fed,all without supplementary food. 9.1% of the infants showed corresponding gastrointestinal symptoms, such as bloating, increased crying, decreased milk intake, and laborious defecation. 87.1% of the infants received medical treatment, including glycerin enema, probiotics, and Chinese herbal preparations, with an effective treatment rate of 7.8%. 38.7% of infants have undergone medical examination, including abdominal ultrasound, X-ray film / barium enema, blood test, etc, the positive rate is 14.8%. The duration of fecal retention in 53% of infants was ≤ 2 months, 22.6% between 2–3 months, 24.4% ≥ 3 months, with an average of 2.6 ± 1.1 months. At the age of followed up to 1 year, 16.8% of infants developed functional constipation(FC). Compared with other infants with normal defecation, there was no significant difference in age, frequency of stool, the proportion of breast milk feeding and receiving treatment, and there was a significant difference in the duration of fecal retention. The duration of FC group was longer than normal defecation group by which was 3.49 ± 0.83 months.4) Conclusions: Infants with fecal retention are more likely to develop FC at age 1 than general population, and may be positively related to the duration of fecal retention.

scholarly journals Early Corticosteroid Therapy for Mycoplasma pneumoniae Pneumonia Irrespective of Used Antibiotics in Children

2019 ◽  
Author(s):  
Eun-Ae Yang ◽  
Hun-Mi Kang ◽  
Jung-Woo Rhim ◽  
Jin-Han Kang ◽  
Kyung-Yil Lee
Keyword(s):  
Disease Progression ◽  
Mycoplasma Pneumoniae ◽  
Corticosteroid Therapy ◽  
Adverse Reactions ◽  
Clinical Symptoms ◽  
Severe Pneumonia ◽  
Oral Prednisolone ◽  
Intravenous Methylprednisolone ◽  
The Mean ◽  
A Prospective Study

Antibiotics&rsquo; effect on Mycoplasma pneumoniae (MP) infection still remains controversial. A prospective study of 257 children with MP pneumonia during a recent epidemic (2015-2016) was conducted. All MP pneumonia patients were treated with corticosteroids within 24-36 h after admission. Initially, oral prednisolone (1 mg/kg) or intravenous methylprednisolone (IVMP) (1-2 mg/kg) was administered for mild pneumonia patients, and IVMP (5 -10 mg/kg/day) for severe pneumonia patients. If patients showed persistent fever for 36-48 hours or disease progression, additive IVMP (5 mg/kg or 10 mg/kg) was given. Eighty-five patients received only a broad-spectrum antibiotic without macrolide. The mean age and the male:female ratio were 5.6 &plusmn; 3.1 years, respectively. Seventy-four percent of patients (190/257) showed immediate defervescence within 24 h, and 95.7% (246/257) of patients showed defervescence within 72 h with improvements in clinical symptoms. Eight patients who received additive IVMP also showed clinical improvement within 48 h without adverse reactions. There were no clinical or laboratory differences between patients treated with a macrolide (n = 172) and without (n = 85). Early corticosteroid therapy might reduce disease morbidity and prevent disease progression in MP pneumonia patients without side effects, and antibiotics may have limited effects on MP infection.

scholarly journals Potential Factors Affected Safety and Efficacy of Transcatheter Plug Closure for Pediatric Hemoptysis with Anomalous Bronchial Arteries

2019 ◽  
Vol 2019 ◽  
pp. 1-9
Author(s):  
Hong-Yu Kuang ◽  
Qiang Li ◽  
Ping Xiang ◽  
Chuan Feng ◽  
Qi-Jian Yi ◽  
...  
Keyword(s):  
Clinical Symptoms ◽  
Controlled Trial ◽  
Statistical Significance ◽  
Safe Procedure ◽  
Bronchial Arteries ◽  
Safety And Efficacy ◽  
Mycoplasma Pneumonia ◽  
Potential Factors ◽  
Medical University ◽  
Nonrecurrence Group

Objective. To evaluate the safety and efficacy of interventional care in pediatric hemoptysis for anomalous bronchial arteries (BAs) and to identify the potential factors resulting in hemoptysis recurrence. Methods. 20 children complained of hemoptysis were diagnosed with anomalous BAs. All patients received transcatheter plug occlusion in Department of Cardiology, Children’s Hospital of Chongqing Medical University. The safety and efficacy were evaluated according to clinical symptoms and images monitoring of enrolled subjects grouped as recurrence group and nonrecurrence group. The potential factors causing hemoptysis recurrence were reviewed and summarized. Results. No deaths were recorded in a follow-up. Otherwise, hemoptysis recurrence was found in 8 subjects for 14 times, accounting for about 40%. Compared with nonrecurrence group, it indicated a statistical significance in hemoglobin levels (P=0.049), mycoplasma pneumonia particle assays (MP-PA) titers (P=0.030), and number of anomalous BAs (P=0.020). Meanwhile, 50% recurrent scenarios were associated with a respiratory infection by microbiological assessment before transcatheter plug occlusion. The repeat occlusion was applied for unclosed BAs leading to visual recurrent hemoptysis, the average interval time of which was 5.4 ± 3.6 mon. Conclusion. The data from this retrospective study have shown that transcatheter plug occlusion is a relatively safe procedure with a low mortality. The number of abnormal BAs has been identified as a highly significant predictor of recurrence, and the role of MP and other potential factors should be verified in a multicenter, larger sample size, and randomized controlled trial.

Combined Irinotecan and Oxaliplatin Plus Granulocyte Colony-Stimulating Factor in Patients With Advanced Fluoropyrimidine/Leucovorin-Pretreated Colorectal Cancer

1999 ◽  
Vol 17 (3) ◽  
pp. 902-902 ◽  
Author(s):  
Werner Scheithauer ◽  
Gabriela V. Kornek ◽  
Markus Raderer ◽  
Julia Valencak ◽  
Georg Weinländer ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Adverse Reactions ◽  
Gastrointestinal Symptoms ◽  
Hematologic Toxicity ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Time To Treatment Failure ◽  
Grade 3 ◽  
Stimulating Factor

PURPOSE: To evaluate the efficacy and tolerance of combined irinotecan and oxaliplatin in patients with advanced colorectal cancer pretreated with leucovorin-modulated fluoropyrimidines. PATIENTS AND METHODS: Thirty-six patients with metastatic colorectal cancer, who progressed while receiving or within 6 months after discontinuing palliative chemotherapy with fluoropyrimidines/leucovorin, were enrolled onto this study. Treatment consisted of oxaliplatin 85 mg/m2 on days 1 + 15 and irinotecan 80 mg/m2 on days 1 + 8 + 15 every 4 weeks. Depending on the absolute neutrophil counts (ANC) on the day of scheduled chemotherapeutic drug administration, a 5-day course of granulocyte colony-stimulating factor (G-CSF) 5 μg/kg/d was given. RESULTS: The overall response rate was 42% for all 36 assessable patients (95% confidence interval, 26% to 59%), including two complete remissions (6%). Thirteen additional patients (36%) had stable disease, and only eight (22%) progressed. The median time to treatment failure was 7.5 months (range, 1 to 13.5+ months). After a median follow-up time of 14 months, 19 patients (53%) are still alive. Hematologic toxicity was commonly observed, although according to the ANC-adapted use of G-CSF (in 31 patients during 81 of 174 courses), it was generally mild: grade 3 and 4 granulocytopenia occurred in only five and two cases, respectively. The most frequent nonhematologic adverse reactions were nausea/emesis and diarrhea, which were rated severe in 17% and 19%, respectively. CONCLUSION: Our data suggest that the combination of irinotecan and oxaliplatin with or without G-CSF has substantial antitumor activity in patients with progressive fluoropyrimidine/leucovorin-pretreated colorectal cancer. Overall toxicity was modest, with gastrointestinal symptoms constituting the dose-limiting side effects. Further evaluation of this regimen seems warranted.

Photodynamic therapy for preinvasive vaginal cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 5592-5592
Author(s):  
Viktoria A. Ivanova ◽  
Ekaterina V. Verenikina ◽  
Vera P. Nikitina ◽  
Oksana E. Zhenilo ◽  
Anna Yu. Ardzha
Keyword(s):  
Photodynamic Therapy ◽  
Adverse Reactions ◽  
Clinical Symptoms ◽  
Visual Observation ◽  
Vaginal Cancer ◽  
Complete Regression ◽  
Simultaneous Irradiation ◽  
Atypical Cells ◽  
Stratified Squamous Epithelium

5592 Background: Photodynamic therapy (PDT) is an effective method for the treatment of various cancers resulting in apoptosis, autophagy and ischemic necrosis of irradiated tissues. The purpose of the study was to analyze the efficacy of PDT for pre-invasive vaginal cancer treatment. Methods: PDT results were studied in 20 patients aged 32-65 years with verified pre-invasive vaginal cancer. All patients received PDT with the Latus diode laser and Photolon or Photolan photosensitizers. The effect was evaluated with extended colposcopy. The criteria for efficiency included normalization of the colposcopic picture and the absence of atypical cells. The sizes of the irradiation fields varied from 1.5 to 2 cm, the number of fields - from 1 to 4, the power density - from 0.1 to 0.17 W/cm2, the light dose - from 40 to 100 J/cm2. The duration of a PDT session varied from 10 to 30 min, depending on the number of irradiation fields. The irradiation field necessarily included an area of normal tissue 3-5 mm surrounding the lesion. 4 to 6 sessions were required to restore the normal layer of stratified squamous epithelium. The antitumor efficacy of PDT was evaluated based on the results of visual observation of changes in the area of the treated pathological foci and information on the presence or absence of clinical symptoms of the disease 1 and 3 months after the treatment (WHO criteria). Results: Complete regression was registered in 100% of patients after 3 months. Repeated courses of PDT were required in cases with a wide spread of pathological foci and the impossibility of their simultaneous irradiation. At follow-up after 1 month, 3 of 20 patients (15%) showed local foci of atypical changes in the epithelium managed with repeated PDT courses. In 6 months, stable remission of the disease clinical symptoms in the treated pathological foci was registered. The results of the cytological study performed 3 months after PDT were normal in 100% patients; no negative changes were registered 6 and 12 months after PDT. Conclusions: The results of PDT in the treatment of patients with pre-invasive vaginal cancer demonstrated its high therapeutic efficacy and a minimal number of adverse reactions, which allows recommending PDT in the treatment of pre-invasive vaginal cancer.

scholarly journals Gastrointestinal symptoms characteristics of coronavirus disease 2019 patients: a cohort study

2020 ◽  
Author(s):  
Yong Wang ◽  
Bin Pei ◽  
Guoxin Huang ◽  
Shengduo Pei ◽  
Gaojing Qu ◽  
...  
Keyword(s):  
Cohort Study ◽  
Clinical Symptoms ◽  
Gastrointestinal Symptoms ◽  
Disease Process ◽  
Abdominal Discomfort ◽  
Distribution Model ◽  
Course Of Disease ◽  
Symptom Frequency ◽  
The Mean

Abstract Backgroud: To describe the frequency and distribution characteristics of gastrointestinal symptoms of coronavirus disease 2019 (COVID-19) patients.Methods: As a cohort study, all confirmed COVID-19 patients with gastrointestinal symptoms at Xiangyang No.1 people’s hospital were included until February 21st, 2020. Course of disease no less than 21 days.Gastrointestinal symptoms relevant data were extracted and analyzed. The frequency histograms of the symptoms were plotted. Main symptom characteristics were summarized.Results: Of 50 included patients with gastrointestinal symptoms, 21 were male, 29were female. The mean age was 53 (SD 16) years. Course of disease ranged from 21 to 34 days with a median of 26 days. Among all patients, 16 were critically ill and five died, 12 discharged. Thirty-one clinical symptoms occurred 3168 times in total, 6 gastrointestinal symptoms occurred 439 (13.86%) times and 25 non-gastrointestinal symptoms occurred 2 729(86.14%) times. All symptoms and non-gastrointestinal symptoms distributed in 1 to 34 days, reached peak on 6th day of follow up, first seven days were the fastigium and decreasing in the rest days. Gastrointestinal symptoms mainly distributed in 1 to 34 days, reached a peak of 36 times per day on 6th of follow-up with a fastigium during 6 to 12 day, showed a trend of rise first and then fall. Nausea, vomit and abdominal discomfort occurred 133, 70 and 62 times, respectively.Conclusions: A symptom frequency to time distribution model could describe the disease process quantitatively, indicating the change law of gastrointestinal symptoms and the organ damages in gastrointestinal system, could help us to better understand and treat the new disease. Females showed higher incidence of gastrointestinal symptoms, whether there is a sex difference in susceptibility needs to be further confirmed.Trial regitration: retrospectively registeredAuthors Guoxin Huang and Shengduo Pei contributed equally to this work.

Sign in / Sign up

Export Citation Format

Share Document